%0 Journal Article
%T Are proton pump inhibitors a new antidiabetic drug? A cross sectional study
%A Diana Boj-Carceller
%A Pilar Bocos-Terraz
%A Miguel Moreno-Vernis
%A Alejandro Sanz-Paris
%J World Journal of Diabetes
%D 2011
%I Baishideng Publishing Group Co. Limited
%R 10.4239/wjd.v2.i12.217
%X AIM: To investigate the effect of proton pump inhibitors (PPIs) on glycemic control (HbA1c) in type 2 diabetic patients. METHODS: A cross-sectional study of consecutive in-patients admitted to hospital in any department during the first semester of the year 2010 who had a recent HbA1c measurement. The study excluded those with a diagnosis of hyperglycemic decompensation, diabetic onset or pregnancy. It compared HbA1c levels of those taking PPIs and those not. RESULTS: A total of 97 patients were recruited. The average HbA1C level was 7.0% ¡À 1.2%. Overall PPI consumption was 55.7%. HbA1c was significantly lower in individuals who took PPIs: -0.6%, 95% CI: -0.12 to -0.83. People who used PPIs with some type of insulin therapy had a HbA1c reduction by -0.8%, 95% CI: -0.12 to -1.48. For the rest of subgroup analysis based on the antidiabetic drug used, PPI consumption always exhibited lower HbA1c levels. CONCLUSION: PPIs seems to be consistently associated with better glycemic control in type 2 diabetes. HbA1c reduction observed is similar to incretin-based therapies.
%K Proton pump inhibitors
%K Diabetes mellitus
%K Drug therapy
%K Hypoglycemic agents
%K Incretins
%U http://www.wjgnet.com/1948-9358/full/v2/i12/217.htm